Alpha Teknova (TKNO)
NASDAQ:TKNO
Want to see TKNO full AI Analyst Report?
Top Page
Alpha Teknova
(NASDAQ:TKNO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$4.00
▲(77.78% Upside)
Action:Reiterated
Date:05/09/26
The score is held back primarily by weak financial performance—persistent losses and ongoing cash burn despite improving revenue and gross margin. Offsetting this, technical indicators show improving near-term momentum, and the latest earnings call supports a measured improvement narrative with reiterated guidance and better operating metrics, though profitability and cash runway risks remain.
Positive Factors
Gross margin recovery
Gross margin recovering to the mid-30s from much lower levels signals improved pricing, product mix, and manufacturing efficiency. Sustained mid-30s margins materially reduce the revenue needed to reach positive adjusted EBITDA and improve the feasibility of self-funded growth over the next 2–3 years.
Negative Factors
Persistent unprofitability
Sustained GAAP losses and deeply negative margins indicate the business has not yet converted revenue scale into operating profitability. Continued negative operating and free cash flow implies ongoing financing needs and raises execution risk until adjusted EBITDA turns consistently positive.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin recovery
Gross margin recovering to the mid-30s from much lower levels signals improved pricing, product mix, and manufacturing efficiency. Sustained mid-30s margins materially reduce the revenue needed to reach positive adjusted EBITDA and improve the feasibility of self-funded growth over the next 2–3 years.
Read all positive factors
Alpha Teknova (TKNO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$208.56M
Dividend YieldN/A
Average Volume (3M)318.88K
Price to Earnings (P/E)―
Beta (1Y)1.11
Revenue Growth9.29%
EPS Growth31.97%
CountryUS
Employees173
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.33
Shares Outstanding53,614,030
10 Day Avg. Volume259,294
30 Day Avg. Volume318,881
Financial Highlights & Ratios
PEG Ratio0.27
Price to Book (P/B)2.96
Price to Sales (P/S)5.02
P/FCF Ratio-20.75
Enterprise Value/Market Cap1.05
Enterprise Value/Revenue5.24
Enterprise Value/Gross Profit15.71
Enterprise Value/Ebitda-21.95
Forecast
1Y Price Target
$9.50Price Target Upside322.22% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.34
Revenue Forecast (FY)$43.82M
Alpha Teknova Business Overview & Revenue Model
Company Description
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines,...
How the Company Makes Money
Alpha Teknova makes money by selling life-sciences reagents and related materials to customers that need consistent, scalable inputs for laboratory and pre-commercial/clinical workflows. Its revenue model is largely product sales and manufacturing...
Alpha Teknova Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 12, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone: the company reported solid top-line growth (13% YoY), a pronounced 85% increase in Clinical Solutions, improved gross margin and adjusted EBITDA, operational scaling initiatives, and disciplined commercial investments aimed at driving ~20% growth in 2027. However, material risks remain including a persistent GAAP net loss, continued negative adjusted EBITDA, modest Lab Essentials growth, high fixed-cost structure with a roughly 70% marginal cash drop-through, and dependence on broader biotech funding recovery. Management reiterated a conservative 2026 guide while outlining a credible plan for improved profitability and growth in 2027.Positive Updates
Overall Revenue Growth
Total revenue grew 13% year over year in Q1 2026; this is the first Q1 in nearly three years with revenue above $11 million.
Negative Updates
Continued Net Loss
Net loss remained $4.6 million in Q1 2026 (negative $0.08 per diluted share), essentially flat with Q1 2025 (negative $0.09), indicating the company is still not GAAP profitable.
Read all updates
Q1-2026 Updates
Positive
Negative
Overall Revenue Growth
Total revenue grew 13% year over year in Q1 2026; this is the first Q1 in nearly three years with revenue above $11 million.
Read all positive updates
Company Guidance
The company reiterated 2026 revenue guidance of $42–$44 million (midpoint ≈ 6% growth vs. 2025), expects full‑year gross margin in the mid‑30s, plans roughly $2.0 million of incremental annual commercial spend (split between sales and marketing) with impact visible by early 2027, and continues to target full‑year free cash outflow of less than $10.0 million; Q1 specifics included revenue topping $11.0 million (up 13% YoY) with Lab Essentials $8.4M (+3%) and Clinical Solutions $2.1M (+85%), gross profit $3.8M (34.2% margin), operating expenses $8.1M, net loss $4.6M (−$0.08/share), adjusted EBITDA −$2.0M (vs. −$2.5M prior year), cash of $17.8M and total borrowings $13.2M, a ~70% marginal cash drop‑through rate on incremental revenue, and a stated ~$52–$57M annualized revenue threshold to reach adjusted EBITDA positivity (with the company aiming for a positive adjusted EBITDA quarter by 2027).Alpha Teknova Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
58
Neutral
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 41.80M | 40.52M | 37.74M | 36.68M | 41.42M | 36.89M |
| Gross Profit | 13.93M | 13.44M | 7.23M | 10.30M | 17.48M | 17.62M |
| EBITDA | -9.97M | -10.15M | -19.57M | -25.54M | -25.69M | -9.13M |
| Net Income | -17.17M | -17.26M | -26.75M | -36.78M | -47.47M | -9.80M |
Balance Sheet | ||||||
| Total Assets | 98.66M | 103.58M | 118.77M | 128.59M | 152.26M | 166.51M |
| Cash, Cash Equivalents and Short-Term Investments | 4.31M | 5.91M | 30.40M | 28.48M | 42.24M | 87.52M |
| Total Debt | 14.66M | 15.15M | 30.17M | 30.46M | 42.31M | 11.87M |
| Total Liabilities | 33.73M | 34.81M | 36.38M | 38.55M | 52.38M | 23.31M |
| Stockholders Equity | 64.92M | 68.78M | 82.39M | 90.04M | 99.89M | 143.20M |
Cash Flow | ||||||
| Free Cash Flow | -8.87M | -9.79M | -13.52M | -26.75M | -55.55M | -28.95M |
| Operating Cash Flow | -7.70M | -8.65M | -12.39M | -18.81M | -27.40M | -9.07M |
| Investing Cash Flow | 8.72M | 10.70M | -27.27M | -7.74M | -28.15M | -17.52M |
| Financing Cash Flow | -85.00K | 151.00K | 14.89M | 12.80M | 10.27M | 110.79M |
Alpha Teknova Technical Analysis
Positive
2.25
Price Trends
3.21
Positive
3.03
Positive
3.92
Negative
Market Momentum
0.19
Positive
60.79
Neutral
58.52
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TKNO, the sentiment is Positive. The current price of 2.25 is below the 20-day moving average (MA) of 3.66, below the 50-day MA of 3.21, and below the 200-day MA of 3.92, indicating a neutral trend. The MACD of 0.19 indicates Positive momentum. The RSI at 60.79 is Neutral, neither overbought nor oversold. The STOCH value of 58.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TKNO.
Alpha Teknova Risk Analysis
Alpha Teknova disclosed 70 risk factors in its most recent earnings report. Alpha Teknova reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Alpha Teknova Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $645.28M | 3.52 | -38.88% | ― | 13.80% | ― | |
53 Neutral | $164.11M | -14.36 | -35.57% | ― | 15.00% | 3.18% | |
52 Neutral | $208.56M | -8.50 | -24.32% | ― | 9.29% | 31.97% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $738.36M | -8.35 | -29.40% | ― | 610.96% | -18.43% | |
42 Neutral | $184.92M | -2.33 | -146.68% | ― | 0.47% | -430.88% |
* Healthcare Sector Average
TKNO
Alpha Teknova
3.89
-1.98
-33.73%
IRWD
Ironwood Pharma
3.92
3.35
592.58%
LFCR
Lifecore Biomedical
4.93
-1.79
-26.64%
SXTC
China SXT Pharmaceuticals
1.66
-230.84
-99.29%
DERM
Journey Medical Corp
5.96
-1.81
-23.29%
BIOA
BioAge Labs, Inc.
16.61
12.66
320.51%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.